Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MEK1 is required for the development of NRAS-driven leukemia.

Oncotarget - 6 Dec 2016

Nowacka Joanna D, Baumgartner Christian, Pelorosso Cristiana, Roth Mareike, Zuber Johannes, Baccarini Manuela

Abstract excerpt

The dual-specificity kinases MEK1 and MEK2 act downstream of RAS/RAF to induce ERK activation, which is generally considered protumorigenic. Activating MEK mutations have not been discovered in leukemia, in which pathway activation is caused by mutations in upstream components such as RAS or Flt3. The anti-leukemic potential of MEK inhibitors is being tested in clinical trials; however, downregulation of MEK1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Expression Regulation, Leukemic
Share to HL-60 Cells

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to K562 Cells

Share to Leukemia

Share to MAP Kinase Kinase 1

Share to Proto-Oncogene Proteins c-myc

Share to THP-1 Cells

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 27741509
DOI: 10.18632/oncotarget.12555
PMCID: PMC5348309

Genes

NRAS
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MEK1 is required for the development of NRAS-driven leukemia.PMID 27741509Read ↗

Preclinical efficacy of MEK inhibition in Nras-mutant AML.Semantic proximity Read ↗

Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require ErkSemantic proximity Read ↗

Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.Semantic proximity Read ↗

Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.Semantic proximity Read ↗

Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.Semantic proximity Read ↗

Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation.Semantic proximity Read ↗

Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts.Semantic proximity Read ↗

Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.Semantic proximity Read ↗

Signal transduction cascade shared by epidermal growth factor and platelet-derived growth factor is a major pathway for oncogenic transformation in NRK cells.Semantic proximity Read ↗

Endogenous K-ras signaling in erythroid differentiation.Semantic proximity Read ↗

Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.Semantic proximity Read ↗

NRAS-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3Kα.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.